DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will participate in a fireside chat at the Baird Global Healthcare Conference on Tuesday, September 12, at 10:15 am ET.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.
Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.
Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and Twitter @Fortrea.
Fortrea Contacts
Hima Inguva (Investors) – 877-495-0816, This email address is being protected from spambots. You need JavaScript enabled to view it.
Sue Zaranek (Media) – 919-943-5422, This email address is being protected from spambots. You need JavaScript enabled to view it.
Kate Dillon (Media) – 646-818-9115, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.11 |
Daily Change: | -0.16 -3.04 |
Daily Volume: | 1,374,845 |
Market Cap: | US$462.660M |
June 24, 2025 June 11, 2025 May 12, 2025 March 03, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load